Pasternak Andy 4

What Happened
Andy Pasternak, a director of Context Therapeutics (CNTX), received a derivative equity award on June 24, 2026 covering 45,000 shares. The Form 4 reports the award as acquired at $0.00 per share (total cash paid $0.00) and classifies the transaction as a grant/award (code A). According to the filing footnote, the award is an option that vests and becomes exercisable on the earlier of June 24, 2027 (one-year anniversary) or the company’s 2027 annual meeting, subject to continued service.

Key Details

• Transaction date: 2026-06-24 (Form 4 filed 2026-06-26 — within typical 2-business-day reporting window).
• Transaction type/code: Grant/Award (A); derivative award (option).
• Amount: 45,000 shares (derivative). Reported acquisition price: $0.00; reported cash paid: $0.00.
• Vesting/exercise: Vests and becomes exercisable earlier of 6/24/2027 or the 2027 annual meeting, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed June 26, 2026 for a June 24, 2026 grant — appears timely under Form 4 rules.

Context
This was a director compensation grant (an option award) rather than an open-market buy or sale. Such awards are common for board compensation; they do not represent an immediate cash investment or sale. Because it’s a derivative option with vesting conditions, there’s no immediate change in market exposure until the option vests and is exercised.